The Zhitong Finance App notes that in addition to focusing on the quarterly results announced on Tuesday, investors in Novartis (NVS.US) are also looking at the results of three major drug trials to be announced in the second half of this year. These results are seen as the key to proving that the Swiss pharmaceutical company enjoys a reasonable premium valuation.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.